Location of Repository

Salvage for cervical recurrences of head and neck cancer with dissection and interstitial high dose rate brachytherapy

By Antonio Cassio Assis Pellizzon, João Victor Salvajoli, Luiz Paulo Kowalski and Andre Lopes Carvalho


Salvage therapy in head and neck cancer (HNC) is a controversy issue and the literature is scarce regarding the use of interstitial high-dose rate brachytherapy (I-HDR) in HNC. We evaluated the long-term results of a treatment policy combining salvage surgery and I-HDR for cervical recurrences of HNC. Charts of 21 patients treated from 1994 to 2004 were reviewed. The crude local control rate for all patients was 52.4%. The 5- and 8-years overall (OS) and local relapse-free survival (LRFS) rates were 50%, 42.9%, 42.5% and 28.6%, respectively. The only predictive factor associated to LFRS and OS was negative margin status (p = 0.0007 and p = 0.0002). We conclude that complete surgery is mandatory for long term control and the doses given by brachytherapy are not high enough to compensate for microscopic residual disease after surgery

Topics: Research
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:1559626
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles



    1. (1997). AG: Fractionated high-dose-rate and pulsed-dose-rate brachytherapy: first clinical experience in squamous cell carcinoma of the tonsillar fossa and soft palate.
    2. (1997). Committee on Cancer: Purposes and principles of staging.
    3. (2003). Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.
    4. (2001). G: The importance of interstitial radiotherapy in the treatment of the base of tongue tumors: a retrospective analysis. Neoplasma
    5. (2002). Head and neck brachytherapy. Semin Radiat Oncol
    6. (1985). Interstitial brachytherapy with Ir-192 low-dose-rate in the treatment of primary and recurrent cancer of the oral cavity and oropharynx. Review of 318 patients treated between
    7. (2003). Jauffret E: Brachytherapy in head and neck cancers. Cancer Radiother
    8. (2005). LP: Interstitial high-dose-rate brachytherapy combined with cervical dissection on head and neck cancer. Head Neck
    9. (2004). Peiffert D: Postoperative brachytherapy alone and combined postoperative radiotherapy and brachytherapy boost for squamous cell carcinoma of the oral cavity, with positive or close margins. Head Neck
    10. (1998). Pellizzon ACA, Kowalski LP: Possibilities of high dose rate brachytherapy on treatment of head and neck cancer.
    11. (2002). SK: High dose rate brachytherapy for early stage oral tongue cancer. Head Neck
    12. (2003). The role of pulsed-doserate brachytherapy in previously irradiated head-and-neck cancer. Brachytherapy
    13. (1996). Threlfall WJ: Seven fractions of twice daily high dose-rate brachytherapy for node-negative carcinoma of the mobile tongue results in loss of therapeutic ratio. Radiother Oncol
    14. (2002). Update on chemoradiotherapy for head and neck cancer. Curr Opin Oncol
    15. (2004). Villaret DB: Postoperative irradiation for squamous cell carcinoma of the oral cavity: 35-year experience. Head Neck
    16. (2001). Zuraw L: Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: a systematic review of the published literature with subgroup analysis. Head Neck

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.